Highly Focused Radiation May Curb Oligoprogression

Abstract

Findings from the randomized phase II CURB trial indicate that using stereotactic body radiation therapy to target oligoprogression in patients with non-small cell lung cancer significantly prolongs progression-free survival compared with standard systemic treatment. However, the same approach does not benefit patients with breast cancer.